FDA Approves First Pill to Fight Pancreatic Cancer
After decades of failed attempts, a new daily pill called daraxonrasib nearly doubles survival time for pancreatic cancer patients by targeting a protein mutation once thought "undruggable." The FDA approved it six months early, offering fresh hope for one of medicine's deadliest challenges.
A breakthrough pill just became the first drug to successfully block the mutated protein driving more than 90% of pancreatic cancer cases, solving a puzzle that stumped scientists for decades.
The FDA gave expedited approval to daraxonrasib this week, clearing it for sale as Rasonque six months ahead of schedule. The daily pill works by using what researchers describe as "molecular glue" to stick to Kras mutations, proteins that fuel tumor growth but were long considered impossible to target with medication.
In a study of 500 patients whose spreading cancer had stopped responding to chemotherapy, those taking the new drug lived a median of 13.2 months compared to 6.7 months for those continuing chemotherapy. Patients also experienced fewer severe side effects.
Pancreatic cancer kills more than 52,000 Americans each year, with only 13% of patients surviving five years after diagnosis. It's particularly deadly because symptoms rarely appear before the disease spreads to other organs.
The drug gained attention earlier this year when former Nebraska Senator Ben Sasse described experiencing less pain while taking it during a 60 Minutes interview. Public demand surged so dramatically that the FDA allowed early access for qualifying patients before official approval.
Revolution Medicines, the California company behind the pill, is now testing the same technology against lung cancer and other diseases driven by Kras mutations. Doctors treating pancreatic cancer say the approval may accelerate development of dozens of experimental treatments currently in testing.
Why This Inspires
Unlike breast cancer, lung cancer, and other diseases that now have multiple treatment options beyond chemotherapy, pancreatic cancer has resisted progress. The approval of daraxonrasib represents the first major advance in years for patients facing one of oncology's toughest battles.
The drug's success proves that even "undruggable" targets can be conquered with persistence and creativity. What seemed impossible to an entire generation of researchers is now a daily pill that's doubling survival time and reducing pain.
After decades of disappointment, pancreatic cancer patients finally have reason to hope.
More Images
Based on reporting by Google News - New Treatment
This story was written by BrightWire based on verified news reports.
Spread the positivity!
Share this good news with someone who needs it
